Recombinant ACT35 (Pogalizumab Biosimilar) antibody
The Humanized Chimeric anti-ACT35 (Pogalizumab Biosimilar) antibody (ABIN7597916) specifically detects ACT35 (Pogalizumab Biosimilar).
The antibody is reactive with Human samples.
Catalog No. ABIN7597916
$401.14
Plus shipping costs $50.00, if applicable $20.00 dry ice
Shipping to:
United States
Delivery in 12 to 15 Business Days
Quick Overview for Recombinant ACT35 (Pogalizumab Biosimilar) antibody (ABIN7597916)
Target
ACT35 (Pogalizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Humanized
Clonality
Chimeric
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Research Grade Pogalizumab Biosimilar Antibody
-
Specificity
- ACT35 antigen, TXGP1L, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TNFRSF4, OX40L receptor, CD134
-
Purification
- Protein A or G purified from cell culture supernatant.
-
Purity
- >95 % by SDS-PAGE.
-
Isotype
- IgG1 kappa
-
-
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1.66 mg/mL
-
Buffer
- 0.01M PBS, pH 7.4.
-
Storage
- 4 °C,-20 °C,-80 °C
-
Storage Comment
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
-
Expiry Date
- 12 months
-
-
- ACT35 (Pogalizumab Biosimilar)
-
Alternative Name
- Pogalizumab Biosimilar
-
Target Type
- Biosimilar
-
Background
- ACT35 antigen, TXGP1L, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TNFRSF4, OX40L receptor, CD134
-
UniProt
- P43489
-
CAS-No
- 1638935-72-4
Target
-
You are here:
